First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens

Joseph Fokam1,2,3,4*, Desire Takou1, Ezechiel Ngoufack Jagni Semengue1,5,6, Georges Teto1, Grace Beloumou1, Beatrice Dambaya1, Maria-Mercedes Santoro6, Leonella Mossiang7, Serge Clotaire Billong2,4,8, Fatim Cham9, Samuel Martin Sosso1, Edith Saounde Temgoua9, Aubin Joseph Nanfack1, Sylvie Moudourou1, Nelly Kamgaing1, Rachel Kamgaing1, Joelle Nounouc Ngako Pamen4,10, Mireille Mpoudi Ngole Etame11, Anne-Cecile Z.-K. Bissek2,4,12, Jean-Bosco N. Elat4,8, Emmanuel Eben Moussi1, Vittorio Colizzi1,5,6, Carlo-Federico Perno1,5,13†, Alexis Ndjolo1,3,4†, On behalf of the VIROFORUM

Abstract

Background: Sub-Saharan African countries are transitioning to dolutegravir-based regimens, even for patients with extensive previous drug exposure, including first-generation integrase strand-transfer inhibitors (INSTI) such as raltegravir. Such exposure might have implications on cross-resistance to dolutegravir-based antiretroviral therapies (ART).

(Continued on next page)
Background

Management of treatment-experienced HIV-patients remains very challenging in resource-limited settings where drug options are limited, poor adherence is frequent, and treatment monitoring (viral load essentially) remains sub-optimal [1, 2]. ART program was launched in Cameroon by May 2003, and genotyping drug resistance testing (GRT) is recommended essentially after failing a PI/r-based regimen [3]. Following the recent World Health Organisation (WHO) recommendations, most resource-limited settings, including Cameroon, are transitioning to dolutegravir (DTG)-based regimens for first-, second- and/or third-line ART [3], with no evidence of DTG-resistance reported in West-Central Africa [1, 3], and fewer cases in East Africa [4]. Of note, few studies reported lower rates of cross-resistance between raltegravir (first-generation integrase strand-transfer inhibitor) and dolutegravir (second-generation integrase strand transfer inhibitor) in Europe [5–8]. Exposure to raltegravir has been previously reported in managing patients with multi-resistant HIV in Africa, but little is known on their effects after transitioning to dolutegravir-containing regimens [9]. Understanding the implications of prior exposure to raltegravir in routine clinical practice would serve as footprint for optimal ART-policies in this transition era, particularly in West and Central Africa and also in all resource-limited settings like Cameroon.

Case presentation

This is a 65 years old married man, infected with HIV-1 CRF18_cpx. Therapeutic history, VL, CD4 cell counts and genotypic profiles are summarised in Fig. 1.

The patient was diagnosed with HIV in 2002 and has been on ART for 14 years (since 2006). His initial ART regimen was stavudine (d4T) + lamivudine (3TC) + nevirapine (NVP) from August 2006 to August 2007. NVP was subsequently replaced by efavirenz (EFV) from August 2007 to August 2009. From August 2009, the patient voluntarily stopped treatment and returned to the clinic in 2010 for consultation. In 2010, the patient had a high VL (157,290 RNA copies/ml) and very-low CD4 cell count (87 cells/mm^3). Prior to ART re-initiation in 2010, genotypic resistance testing (GRT) results, interpreted throughout using Stanford HIVDB (http://www.hivdb.stanford.edu) and International AIDS Society mutations list, showed the presence of one resistance associated mutation (RAM) to NRTI (V75I), two non-NRTI RAMs (K103I, V108I). With this mutational profile, the patient was recommended PI/r + 2NRTI but we have no precision on antiretrovirals used thereafter. From 2011 to 2012, the patient was diagnosed co-infected with pulmonary tuberculosis and treated accordingly, classified as WHO clinical stage 3. After completing anti-tuberculosis treatment in 2012, he was lost to follow-up (duration unclear) and later returned for clinical consultation. Following clinical assessment, he was re-initiated with a regimen consisting of ritonavir boosted darunavir (DRV/r) + dolutegravir (RAL) + tenofovir (TDF)
Fig. 1 CD4-cell and viral load monitoring, ART regimens, and resistance profiles since ART-initiation.
+3TC (unclear start date) till November 2017; a period during which adherence was suboptimal. A second GRT was performed and the resulting mutational profile suggested DRV/r(600 mg × 2/day) + DTG(50 mg × 2/day), possibly associated with ritonavir-boosted atazanavir (ATV/r) for its potential capacity to enhance DTG concentrations (https://www.hiv-druginteractions.org/drug_queries/326049/drug_query_interactions) as an optimal regimen. However, the patient was prescribed DRV/r(600 mg × 2/day) + DTG(50 mg × 1/day) + TDF + 3TC from November 2017 to May 2019. In May 2019, the patient was empirically switched to DRV/r(600 mg × 2/day) + DTG(50 mg × 1/day) + abacavir (ABC) + 3TC. Then, ABC was changed to TDF until August 2019 when the third GRT was performed.

Overall, reported VLs remained around 5 Log₁₀ copies/mL while CD4-cell counts were consistently < 200 cells/mm³. Adherence to clinic appointments and drug refill was inconsistent, in spite of adherence supports from health care providers. Apart from anorexia and a 2.8% weight-loss reported over an undefined period, a physical examination, performed in May 2019, was unremarkable [3].

Following GRTs performed on HIV-1 “pol” gene for detecting RAMs and gp120 V3-loop for coreceptor usage (using the geno2pheno method [https://coreceptor.geno2pheno.org/]) at three different time points [10, 11], phylogeny consistently revealed the virus to be HIV-1 CRF18_cpx. All sequences generated were submitted to GeneBank (MN52015 – MN520219).

The first GRT (April 29, 2010) covered the protease (PR) and reverse transcriptase (RT) regions, with high-level resistance to first-generation NNRTI (K103I, V108I) and no major-RAM to NRTI and PI/r.

The second GRT (December 01, 2017) covered PR and RT regions. Detected RAMs were M41L, K70Q, V75I, Q151M, M184V and T215F for NRTI; K103N and V108I for NNRTI; and L10F, K20I, M36I, M46I, I47V, I54L, L63H, L76V, V82S and L89I for PI/r. These mutations revealed high-level resistance to all NRTIs, first generation NNRTIs (EFV and NVP) and to all PI/r, including DRV/r. Another GRT, covering HIV-1 integrase (IN) region, performed on the same plasma aliquot, revealed major RAMs, L74I, E138KQ, G140A, Q148R, and E157Q, to integrate strand transfer inhibitors (INSTI) including raltegravir, dolutegravir, bictegravir and elvitegravir. Viral tropism revealed a CCR5-tropic virus, defined by a false positive rate (FPR) of 60.9%, suggesting eligibility for maraviroc (MRV).

The third GRT (August 08, 2019), encompassing PR, RT and IN regions, showed high-level resistance to NRTI, NNRTI, PI and all INSTI. Additional RAMs were H221HY for NNRTI and S147G for INSTI. Viral tropism was also re-performed and demonstrated CCR5-tropic virus with a slightly reduced FPR (57.0%). Pending access to required innovative regimen, a salvage therapy guided by GRT was recommended, consisting of either “DRV/r(600mg x 2/day), saquinavir/r, TDF+3TC”, or “3TC-monotherapy” which maintains M184V and as such limits the viral replicative fitness. None of the recommendations; in November 2019, VL appeared relatively stable (5.54 Log copies/mL under “DRV/r(600mg x 2/day)+TDF+3TC” and with an active family-centered adherence monitoring. Following intensified/close adherence strategy implemented, the patient is compliant to treatment but the latest plasma viral load remains high, with a slight increment (5.86 Log copies/mL on January 27, 2020), which confirms the need of innovative drugs and close case surveillance, including MRV that is not locally available [3].

Discussion
To the best of our knowledge, this is the very first clinical case in West and Central Africa of complete four-class multidrug resistance to all antiretrovirals available in resource-limited settings with complete loss of DRV/r and DTG efficacies. Of note, previous report from Cameroon showed a case of successful raltegravir-containing ART for managing a case of multidrug-class-resistance [9]. Thus, patients with similar therapeutic management within the country might merit a close monitoring to ensure a successful management in case of ART failure with multi-drug resistance [9]. Fewer cases of four-class HIVDR have been recently reported mainly in East and southern African countries, with previous RAL-exposure contributing to ineffectiveness of DTG [4, 12–14]. Though these previously reported clinical cases were attributed to multi-factorial events, the present clinical case was due to recurrent poor adherence, leading to selection and accumulation of RAMs, followed by exposure to suboptimal drug regimens [14–16]. Specifically, previous exposure to RAL (a drug with a low-genetic barrier to resistance) in a context of poor adherence contributed to selecting mutations (E138KQ, G140A, Q148R) conferring cross-resistance to DTG [4, 15, 16]. In a context with 60–80% ADR after ART failure and with documented to RAL has been documented, limiting the use of RAL would preserve DTG for long-term use [1, 16]; and in case of previous exposure to RAL, transition to DTG-based regimens should be guided by GRT in people without VL-suppression [3] and if adopted, DTG-dose should be appropriate [6, 7]. In addition to non-adherence, consistent low CD4-cell counts (despite a relative increase of CD4 after a nadir of 39cells/mm³ is attributable to the use of more potent antiretrovirals), high-VL since ART-initiation, and advanced-age (i.e. > 60 years) are risk-factors that might have contributed to ART-failure [14–16]. Additionally,
the recombinant virus (HIV-1 CRF18_cpx) may explain to a certain extend the rapid emergence of drug-resistance and the predictive CCR5-tropism [17]. The case finding calls essentially for surveillance of acquired (ADR) drug resistance to INSTI in the DTG-era [1–3]. As patient remains clinically stable and sexually active, special patient/family-centered adherence approaches are necessary to limit risk of transmission of four-class drug resistant virus, which may have implications for scale-up of DTG-based ART in resource-limited settings [1, 4, 12–15]. Without any active therapeutic option locally, use of innovative drug combinations consisting preferentially of enfuvirtide, MRV and ibalizumab, is highly recommended (https://www.hiv-druginteractions.org/drug_queries/326049/drug_query_interactions).

Also, as patients on DTG-containing regimens with high baseline VL (> 500,000 copies/mL) might experience challenges in viral suppression, close monitoring as well as specific case surveillance should be required even in resource-limited settings like Cameroon [18].

Conclusion
In the era of transition to DTG-based regimens in resource-limited settings, this clinical case highlights the need for routine ADR population-based surveys to understand the extent of HIVDR to INSTI. Importantly, optimised care/treatment on DTG-containing regimen, alongside adherence support and close VL monitoring, would sustain the efficacy of this therapeutic option. Finally, individual case surveillance after failure to third-line requires genotyping and policies for access to newer drugs in resource-limited settings with similar ART landscapes.

Abbreviations
3TC: Emtricitabine; ABC: Abacavir; ADR: Acquired drug resistance; AIDS: Acquired Immunodeficiency Syndrome; ART: Antiretroviral therapy; ATV/r: Ritonavir boosted Atazanavir; CCR5: C-C chemokine receptor type 5; CD4: Cluster of differentiation four; CRF18_cpx: Circulating recombinant form complex 18; DAT: Stavudine; DRV/r: Ritonavir boosted Darunavir; DTG: Dolutegravir; EFV: Efavirenz; FPR: False positive rate; GP: Envelope complex 18; D4T: Stavudine; DRV/r: Ritonavir boosted Darunavir; NRTI: Non-nucleoside reverse-transcriptase inhibitor; NNRTI: Nucleoside reverse-transcriptase inhibitor; NVP: Nevirapine; PDR: Pretreatment drug resistance; PR/IN: Ritonavir boosted protease inhibitor; Pol: Polymerase; PR: Protease; RAL: Raltegravir; RAMs: Resistance-associated mutations; RNA: Ribonucleic acid; RT: Reverse transcriptase; SSA: Sub-Saharan Africa; TDF: Tenofovir disoproxyl fumarate; V3: Envelope variable region 3; VL: Viral load; WHO: World Health Organization

Acknowledgments
We are appreciative the medical and laboratory staffs involved in the care and monitoring of this patient. We thank Michael Jordan for a thorough review of this manuscript prior to submission.

Authors’ contributions
JF, ENS, MMV, CFP, EST, GT, VC, DT, BD, GB, LM and AN, initiated the manuscript; All the other co-authors: interpreted the data and revised the manuscript; All the authors: approved the final version of the manuscript.

Funding
We also acknowledge financial support from the Chantal Biya International Reference center for research on HIV/AIDS prevention and management (CIRCB), covering the viral load, CD4-cell count and sequencing of HIV-1 protease reverse transcriptase, integrase and V3 loop regions for this patient.

Availability of data and materials
Data and materials are fully available in the manuscript text and in the figure provided. Sequence data generated are deposited in the public repository of GenBank, under the following accession numbers from MNS2015 to MNS2019.

Ethics approval and consent to participate
Administrative authorisation was provided by the Directorate General of the Chantal BIYA International Reference for research on HIV/AIDS prevention and management (CIRCB), under the reference number 0191/019/CIRCB/DTG/SAA/BRH. Ethical clearance was obtained from the National Ethics Committee for Research on Human Health (reference number 2019/06/34/CE/CNERSH/SP of June 14, 2019). Written informed consent was provided.

Consent for publication
Consent has been provided by the patient.

Competing interests
The authors declare they have no personal relationship(s) or financial interests that may have influenced the writing of this report.

Author details
1. Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management, Yaoundé, Cameroon. 2. Faculty of Health Sciences, University of Buea, Buea, Cameroon. 3. National HIV Drug Resistance Working Group, Ministry of Public Health, Yaoundé, Cameroon. 4. Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon. 5. University of Rome Tor Vergata, Rome, Italy. 6. Evangelic University of Cameroon, Bandjoun, Cameroon. 7. HIV Treatment Centre, Yaoundé Central Hospital, Yaoundé, Cameroon. 8. Central Technical Group, National AIDS Control Committee, Yaoundé, Cameroon. 9. World Health Organisation, Regional Office for Africa (AFRO), Brazzaville, Congo. 10. Department of Disease, Epidemics and Pandemics Control, Ministry of Public Health, Yaoundé, Cameroon. 11. HIV Treatment Centre, Military Hospital, Yaoundé, Cameroon. 12. Division of Health Operational Research, Yaoundé, Cameroon. 13. University of Milan, Milan, Italy.

Received: 25 March 2020 Accepted: 6 August 2020
Published online: 26 August 2020

References
1. Grinsztejn B, Hughes MD, Ritz J, et al. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. Lancet HIV. 2019;6(9):e588–600. https://doi.org/10.1016/S2352-3018(19)30146-8.
2. Phillips AN, Stover J, Cambiano V, et al. Impact of HIV drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in sub-Saharan Africa. J Infect Dis. 2017;215(9):1362–5. https://doi.org/10.1093/infdis/jix089.
3. Organization WH. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV - Interim guidance: Who, 2018. https://www.who.int/hiv/pub/guidelines/ARV2018update/en/.
4. Acheng L, Riedel DJ. Dolutegravir resistance and failure in a Kenyan patient. J Infect Dis. 2019;219:165–7.
5. Fourati S, Charpentier C, Amiel C, et al. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. 2015:1–6. https://doi.org/10.1093/jac/dku535.
6. Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in Antiretroviral- Experienced Patients With Raltegravir- and / or Elvitegravir- Resistant HIV-1 : 24-Week Results of the Phase III VIKING-3 Study. J Infect Dis. 2014;210. https://doi.org/10.1093/infdis/jiu051.
7. Eron JJ, Clotet B, Durant J, et al. Safety and Ef fi cacy of Dolutegravir in treatment-experienced subjects with Raltegravir-resistant HIV type 1.
8. Requena S, Treviño A, Cabezas T, et al. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response. J Antimicrob Chemother. 2017;72(7):2083–8. https://doi.org/10.1093/jac/dix090.

9. Aghokeng AF, Kouanfack C, Peeters M, Mpoudi-Ngole E, Delaporte E. Successful Integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class-resistant HIV type 1 group O-infected patient in Cameroon. AIDS Res Hum Retrovir. 2013;29(1):1–3. https://doi.org/10.1089/aid.2012.0196.

10. Fokam J, Salpini R, Santoro MM, et al. Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon. Arch Virology. 2011;156(7):1235–43. https://doi.org/10.1007/s00705-011-0982-3.

11. Fokam J, Bellcoci MC, Armenia D, et al. Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children. Med (United States). 2018;97(13). https://doi.org/10.1097/MD.00000000000010176.

12. Chimibebte C, Katzenstein D, Shamu T, et al. HIV-1 drug resistance and second-line therapy outcomes in patients failing second-line therapy in Zimbabwe. Open Forum Infect Dis. 2018;5(2):1–8. https://doi.org/10.1093/ofid/ofy005.

13. Rossouw TM, Hitchcock S, Botes M. The end of the line? A case of drug resistance to third-line antiretroviral therapy. South Afr J HIV Med. 2016;17(1):3–5. https://doi.org/10.4102/sajhivmed.v17i1.1454.

14. Seatla KK, Avalos A, Moyo S, et al. Four-class drug-resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir-based antiretroviral therapy in Botswana. Aids. 2018;32(13):1899–902. https://doi.org/10.1097/QAD.0000000000001920.

15. Pena MJ, Cheuca N, D’Avolio A, Zarzalejos JM, Garcia F. Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible. Open forum Infect Dis. 2019;6(1):ofy332. https://doi.org/10.1093/ofid/ofy332.

16. Hocqueloux L, Raffi F, Prazuck T, et al. Dolutegravir Monotherapy versus Dolutegravir/Abacavir/Lamivudine for Virologically suppressed people living with chronic human immunodeficiency virus infection: the randomized noninferiority MONotherapy of TiViCAY trial. Clin Infect Dis. 2019;69(9):1498–505. https://doi.org/10.1093/cid/ciy1132.

17. Song H, Giorigi EE, Ganusov VV, et al. Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nat Commun. 2018;9(1):1928. https://doi.org/10.1038/s41467-018-04217-5.

18. Charles K, Mireille M-E, Pierrette OB, et al. Dolutegravir-based or low-dose Efavirenz-based regimen for the treatment of HIV-1. N Engl J Med. 2019;381(9):816–26. https://doi.org/10.1056/nejmoa1904340.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.